What counseling, dosing schedule, drug interaction precautions, and monitoring are recommended for a postmenopausal woman with hormone‑receptor‑positive, HER2‑negative advanced breast cancer who is starting ribociclib (Kisqali) and letrozole therapy?

Ribociclib and Letrozole: Patient Counseling and Management

For a postmenopausal woman with HR-positive, HER2-negative advanced breast cancer starting ribociclib plus letrozole, administer ribociclib 600 mg orally once daily for 21 consecutive days followed by 7 days off (3 weeks on/1 week off) in combination with letrozole 2.5 mg orally once daily continuously until disease progression or unacceptable toxicity 1, 2.

Dosing Schedule

Standard Regimen:

• Ribociclib: 600 mg orally once daily for 21 days, then 7 days off (28-day cycle)
• Letrozole: 2.5 mg orally once daily continuously throughout the 28-day cycle
• Continue until disease progression or unacceptable toxicity 2

Dose Modifications:

• Ribociclib can be reduced to 400 mg, then 200 mg if needed for toxicity management 2, 3
• These reductions maintain efficacy while managing adverse events 3

Critical Monitoring Requirements

Hematologic Monitoring

Blood counts are the most critical monitoring parameter due to high rates of neutropenia (62% grade 3/4) 1:

• Complete blood count (CBC) every 14 days during cycles 1 and 2
• CBC at the start of each subsequent cycle (before day 1)
• Manage neutropenia with dose delays and reductions as needed 4, 2
• Febrile neutropenia is rare (0.6-1%) despite high neutropenia rates 5, 1

Cardiac Monitoring

QTcF prolongation is a significant concern requiring systematic surveillance 2:

• Baseline ECG before starting therapy
• ECG on day 14 of cycle 1, at the beginning of cycle 2
• ECG at the beginning of cycles 3-6, then as clinically indicated
• Avoid in patients with QTc >450 msec at baseline or risk factors for QT prolongation 2

Hepatic Monitoring

Liver function abnormalities occur in 10.2% (grade 3/4) 1:

• Liver function tests (AST, ALT, bilirubin) every 2 weeks for first 2 cycles
• Then at the beginning of subsequent cycles for first 6 cycles
• Then as clinically indicated thereafter 2

Drug Interaction Precautions

Avoid Strong CYP3A Inhibitors/Inducers

Ribociclib is primarily metabolized by CYP3A4 (~84% hepatic metabolism) 3:

Strong CYP3A Inhibitors to AVOID:

• Ketoconazole, itraconazole, clarithromycin, ritonavir
• These significantly increase ribociclib exposure 2, 3

Strong CYP3A Inducers to AVOID:

• Rifampin, phenytoin, carbamazepine, St. John's wort
• These significantly decrease ribociclib exposure 2, 3

Ribociclib as a CYP3A Inhibitor

Ribociclib inhibits CYP3A at 600 mg, increasing exposure of CYP3A substrates 3:

• Avoid concurrent use of sensitive CYP3A substrates with narrow therapeutic indices
• Examples: simvastatin, lovastatin, midazolam

QT-Prolonging Medications

Avoid concurrent medications that prolong QTc interval 2:

• Antiarrhythmics (amiodarone, sotalol)
• Certain antibiotics (moxifloxacin, azithromycin)
• Antipsychotics (haloperidol, ziprasidone)

Proton Pump Inhibitors

No clinically relevant impact on ribociclib exposure - can be used concurrently 3

Patient Counseling Points

Expected Adverse Events

Prepare patients for common toxicities 1, 6:

1. Neutropenia (62% grade 3/4): Usually asymptomatic; emphasize importance of blood monitoring
2. Leukopenia (21.3% grade 3/4): Monitor for signs of infection
3. Nausea (35-45%): Manageable with antiemetics
4. Fatigue (37-40%): Common but usually grade 1-2
5. Diarrhea: Less common than with abemaciclib
6. Liver enzyme elevations (10.2% grade 3/4): Usually asymptomatic

Administration Instructions

• Take ribociclib at approximately the same time each day
• Can be taken with or without food 3
• Swallow tablets whole; do not chew, crush, or split
• If a dose is missed, skip it if <12 hours until next scheduled dose

When to Contact Healthcare Provider

Immediate contact required for:

• Fever ≥100.4°F (38°C) or signs of infection
• Unusual bleeding or bruising
• Severe diarrhea or vomiting
• Palpitations, dizziness, or syncope (cardiac symptoms)
• Yellowing of skin or eyes

Efficacy Expectations

Set realistic expectations based on trial data 1, 6:

• Median progression-free survival: 25.3 months (vs 16.0 months with letrozole alone)
• Objective response rate: 43% (vs 29% with letrozole alone)
• Overall survival benefit demonstrated in MONALEESA-7 (70% vs 46% at 3.5 years in premenopausal women) 1

Special Populations

Premenopausal Women

If patient becomes premenopausal during treatment or was initially premenopausal:

• Add ovarian suppression with goserelin or leuprolide 1
• Same ribociclib/letrozole dosing applies

Elderly Patients

• No dose adjustment needed based on age alone 3
• Ribociclib is well tolerated in elderly patients 7

Hepatic/Renal Impairment

• Mild hepatic or renal impairment: No dose adjustment needed 3
• Moderate-severe impairment: Use with caution; consider dose reduction

Common Pitfalls to Avoid

1. Inadequate monitoring frequency: Missing the every-2-week CBC schedule in cycles 1-2 can lead to undetected severe neutropenia
2. Ignoring QTc monitoring: Cardiac monitoring is mandatory, not optional
3. Continuing through grade 4 neutropenia: Dose interruption and reduction are appropriate and maintain efficacy 3
4. Overlooking drug interactions: Always review medication list for CYP3A inhibitors/inducers and QT-prolonging drugs
5. Discontinuing for manageable toxicity: Dose reductions to 400 mg or 200 mg maintain efficacy while improving tolerability 2, 3